Biodistribution and safety assessment of bladder cancer specific recombinant oncolytic adenovirus in subcutaneous xenografts tumor model in nude mice

Current Gene Therapy

Volumn 12, Issue 2, 2012, Pages 67-76

  Wang, Fang ^a   Wang, Zhiping ^a   Tian, Hongwei ^b   Qi, Meijiao ^a   Zhai, Zhenxing ^a   Li, Shuwen ^a   Li, Renju ^a   Zhang, Hongjuan ^a   Wang, Wenyun ^a   Fu, Shenjun ^a   Lu, Jianzhong ^a   Rodriguez, Ronald ^c   Guo, Yinglu ^d   Zhou, Liqun ^d  

^a LANZHOU UNIVERSITY   (China)

^b GANSU PROVINCIAL HOSPITAL   (China)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d PEKING UNIVERSITY FIRST HOSPITAL   (China)

Author keywords

Biodistribution; Bladder cancer; Gene therapy; Oncolytic adenovirus; Safety assessment

Indexed keywords

E1A PROTEIN; ONCOLYTIC ADENOVIRUS; UROPLAKIN 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BEHAVIOR; BLADDER CANCER; BLOOD TOXICITY; BODY WEIGHT; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG SAFETY; GENE EXPRESSION; LIVER TOXICITY; MALE; MOUSE; NONHUMAN; TUMOR XENOGRAFT; VIRUS REPLICATION;

ADENOVIRIDAE; ADENOVIRUS E1A PROTEINS; ANIMALS; BLOTTING, WESTERN; CELL LINE, TUMOR; CYTOPATHOGENIC EFFECT, VIRAL; GENE THERAPY; GENETIC VECTORS; HEK293 CELLS; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; PROMOTER REGIONS, GENETIC; RECOMBINANT FUSION PROTEINS; RECOMBINATION, GENETIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TISSUE DISTRIBUTION; URINARY BLADDER NEOPLASMS; UROPLAKIN II; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ADENOVIRIDAE; ANIMALIA; MUS; MUS MUSCULUS;

EID: 84860265783     PISSN: 15665232     EISSN: 18755631     Source Type: Journal    
DOI: 10.2174/156652312800099599     Document Type: Article

References (36)

1. Kaufman DS, Shipley WU, Feldman AS. Bladder cancer. Lancet 2009; 374: 239-49.
2. Ghoneim MA, Abol-Enein H. Management of muscle-invasive bladder cancer: an update. Nat Clin Pract Urol 2008; 5: 501-8.
3. ABCM-a C. Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. Lancet 2003; 361: 1927-34.
4. Hussain SA, James ND. The systemic treatment of advanced and metastatic bladder cancer. Lancet Oncol 2003; 4: 489-97.
5. Karamouzis MV, Argiris A, Grandis JR. Clinical applications of gene therapy in head and neck cancer. Curr Gene Ther 2007; 7: 446-57.
6. Kaur B, Cripe TP, Chiocca EA. "Buy one get one free": armed viruses for the treatment of cancer cells and their microenvironment. Curr Gene Ther 2009; 9: 341-55.
7. Brody SL, Crystal RG. Adenovirus-mediated in vivo gene transfer. Ann N Y Acad Sci 1994; 716: 90-101; discussion 101-3.
8. Zhang J, Ramesh N, Chen Y, et al. Identification of human uroplakin II promoter and its use in the construction of CG8840, a urothelium-specific adenovirus variant that eliminates established bladder tumors in combination with docetaxel. Cancer Res 2002; 62: 3743-50.
9. He XD, Wang ZP, Wei HY, et al. Construction of urotheliumspecific recombinant adenovirus and its inhibition in bladder cancer cell. Urol Int 2009; 82: 209-13.
10. Latham JP, Searle PF, Mautner V, et al. Prostate-specific antigen promoter/enhancer driven gene therapy for prostate cancer: construction and testing of a tissue-specific adenovirus vector. Cancer Res 2000; 60: 334-41.
11. Wang D, Wang Z, Tian J, et al. Prostate stem cell antigen enhancer and uroplakin II promoter based bladder cancer targeted tissuespecific vector. Urol Oncol 2008; 28: 164-9.
12. Hoti N, Li Y, Chen CL, et al. Androgen receptor attenuation of Ad5 replication: implications for the development of conditionally replication competent adenoviruses. Mol Ther 2007; 15: 1495-503.
13. Zhai Z, Wang Z, Fu S, et al. Antitumor effects of bladder cancerspecific adenovirus carrying E1A-androgen receptor in bladder cancer. Gene Ther 2012.
14. Hemminki A. From molecular changes to customised therapy. Eur J Cancer 2002; 38: 333-8.
15. Burke J. Virus therapy for bladder cancer. Cytokine Growth Factor Rev 2010; 21: 99-102.
16. Ganly I, Kirn D, Eckhardt G, et al. A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin Cancer Res 2000; 6: 798-806.
17. Jiang H, Gomez-Manzano C, Lang FF, et al. Oncolytic adenovirus: preclinical and clinical studies in patients with human malignant gliomas. Curr Gene Ther 2009; 9: 422-7.
18. Freytag SO, Stricker H, Peabody J, et al. Five-year follow-up of trial of replication-competent adenovirus-mediated suicide gene therapy for treatment of prostate cancer. Mol Ther 2007; 15: 636-42.
19. Freytag SO, Khil M, Stricker H, et al. Phase I study of replicationcompetent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer. Cancer Res 2002; 62: 4968-76.
20. Small EJ, Carducci MA, Burke JM, et al. A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigentargeted oncolytic adenovirus, for the treatment of hormonerefractory, metastatic prostate cancer. Mol Ther 2006; 14: 107-17.
21. DeWeese TL, van der Poel H, Li S, et al. A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Res 2001; 61: 7464-72.
22. Terao S, Shirakawa T, Kubo S, et al. Midkine promoter-based conditionally replicative adenovirus for targeting midkineexpressing human bladder cancer model. Urology 2007; 70: 1009-13.
23. Ramesh N, Ge Y, Ennist DL, et al. CG0070, a conditionally replicating granulocyte macrophage colony-stimulating factor--armed oncolytic adenovirus for the treatment of bladder cancer. Clin Cancer Res 2006; 12: 305-13.
24. Kuroda S, Fujiwara T, Shirakawa Y, et al. Telomerase-dependent oncolytic adenovirus sensitizes human cancer cells to ionizing radiation via inhibition of DNA repair machinery. Cancer Res 2010; 70: 9339-48.
25. Kumar S, Gao L, Yeagy B, et al. Virus combinations and chemotherapy for the treatment of human cancers. Curr Opin Mol Ther 2008; 10: 371-9.
26. Ramesh N, Memarzadeh B, Ge Y, et al. Identification of pretreatment agents to enhance adenovirus infection of bladder epithelium. Mol Ther 2004; 10: 697-705.
27. Wang H, Satoh M, Abe H, et al. Oncolytic viral therapy by bladder instillation using an E1A, E1B double-restricted adenovirus in an orthotopic bladder cancer model. Urology 2006; 68: 674-81.
28. Hamid O, Varterasian ML, Wadler S, et al. Phase II trial of intravenous CI-1042 in patients with metastatic colorectal cancer. J Clin Oncol 2003; 21: 1498-504.
29. Nemunaitis J, Cunningham C, Buchanan A, et al. Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity. Gene Ther 2001; 8: 746-59.
30. Toth K, Djeha H, Ying B, et al. An oncolytic adenovirus vector combining enhanced cell-to-cell spreading, mediated by the ADP cytolytic protein, with selective replication in cancer cells with deregulated wnt signaling. Cancer Res 2004; 64: 3638-44.
31. Working PK, Lin A, Borellini F. Meeting product development challenges in manufacturing clinical grade oncolytic adenoviruses. Oncogene 2005; 24: 7792-801.
32. Engler H, Machemer T, Philopena J, et al. Acute hepatotoxicity of oncolytic adenoviruses in mouse models is associated with expression of wild-type E1a and induction of TNF-alpha. Virology 2004; 328: 52-61.
33. Shayakhmetov DM, Gaggar A, Ni S, et al. Adenovirus binding to blood factors results in liver cell infection and hepatotoxicity. J Virol 2005; 79: 7478-91.
34. Cascallo M, Alonso MM, Rojas JJ, et al. Systemic toxicity-efficacy profile of ICOVIR-5, a potent and selective oncolytic adenovirus based on the pRB pathway. Mol Ther 2007; 15: 1607-15.
35. Tsukuda K, Wiewrodt R, Molnar-Kimber K, et al. An E2Fresponsive replication-selective adenovirus targeted to the defective cell cycle in cancer cells: potent antitumoral efficacy but no toxicity to normal cell. Cancer Res 2002; 62: 3438-47.
36. Lovatt A. Applications of quantitative PCR in the biosafety and genetic stability assessment of biotechnology products. J Biotechnol 2002; 82: 279-300.